Trial Profile
Active surveillance with or without a 6 months Apalutamide treatment in low risk prostate cancer: a phase II randomized multicenter trial.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms PC-ARN
- 06 Jun 2023 Results (n=91) assessing anxiety and depression using the Hospital Anxiety and Depression Scale (HADS) and prostate-specific anxiety using the Memorial Anxiety Scale for Prostate Cancer , presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 18 Feb 2023 Results assessing 1-year safety and quality of life analyses, presented at the 2023 Genitourinary Cancers Symposium.
- 02 May 2017 Planned End Date changed from 27 Mar 2022 to 28 Apr 2022.